A mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine (pig) brain tissue. Contains fragments that mimic the activity of naturally occurring neurotrophic factors (BDNF, NGF, CNTF). Used in 50+ countries for stroke, TBI, and dementia — but NOT approved in the US.
Cerebrolysin is a unique therapeutic peptide preparation consisting of low-molecular-weight neuropeptides (< 10 kDa) and free amino acids derived from enzymatic breakdown of purified porcine brain proteins. It is manufactured by EVER Neuro Pharma (Austria) and has been used clinically in Europe, Asia, and Latin America since the 1970s.
Unlike the other peptides in this encyclopedia, Cerebrolysin is not a single defined sequence but a standardized mixture containing fragments that functionally mimic neurotrophic factors — particularly brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). Its peptide components are small enough to cross the blood-brain barrier.
Cerebrolysin's peptide fragments are believed to bind to neurotrophin receptors (TrkA, TrkB) and activate downstream signaling cascades identical to those triggered by endogenous neurotrophic factors. The PI3K/Akt pathway promotes neuronal survival by inhibiting apoptosis. The MAPK/ERK pathway drives neuronal differentiation and axonal growth. CREB activation promotes expression of genes involved in synaptic plasticity, long-term potentiation, and memory formation.
| Pathway | Effect | Significance |
|---|---|---|
| Neurotrophic mimicry | Small peptides mimic BDNF, NGF, CNTF signaling | Activates survival and growth pathways in neurons without needing full-size neurotrophins |
| BBB penetration | Peptides < 10 kDa cross the blood-brain barrier | Enables systemic (IV/IM) administration rather than intracerebral injection |
| Anti-apoptotic | Activates PI3K/Akt → inhibits caspase cascade | Protects neurons from ischemic and excitotoxic death |
| Synaptogenesis | Promotes new synaptic connections and dendritic branching | May improve functional recovery after brain injury |
| Neurogenesis | Stimulates neural stem cell proliferation in hippocampus | Potential to generate new neurons in adult brain |
| Study | Design | Findings | Level |
|---|---|---|---|
| Acute ischemic stroke | Multiple RCTs, meta-analyses, n=thousands | Some studies show improved neurological recovery at 90 days. Results inconsistent across trials. A large 2020 Cochrane review found low-certainty evidence of benefit. | Level I (mixed/debated) |
| Alzheimer's disease | RCTs, n=several hundred | Some trials show modest cognitive improvement (ADAS-cog). Not consistently replicated. Not accepted as standard therapy. | Level I-II (modest) |
| Traumatic brain injury | RCTs | Some evidence of improved GCS scores and functional outcome. Sample sizes small. | Level II |
| Vascular dementia | Clinical studies | Used extensively in Eastern Europe and Asia. Some evidence of cognitive benefit. | Level II-III |
Generally well-tolerated: Headache, dizziness, and injection site reactions are the most common adverse effects.
Allergic reactions: Risk of allergy to porcine proteins. Contraindicated in patients with known pork allergy.
Seizure risk: Rare reports of seizures, particularly in patients with epilepsy history. Use with caution.
Prion disease concern (theoretical): As a porcine brain-derived product, theoretical concerns about prion transmission exist, though no cases have been reported and manufacturing includes safety steps.
| Jurisdiction | Status |
|---|---|
| FDA | NOT approved. No application submitted. |
| EMA | Not centrally approved, though used in some EU countries. |
| International | Approved and widely used in Austria, Germany, Russia, China, South Korea, and 50+ other countries. |
| Controversy | Western neurologists are generally skeptical due to inconsistent trial results and lack of FDA/EMA approval. Eastern European and Asian neurologists use it routinely. |